Olokizumab not checked
R-Pharm International, LLC · CDP6038
FollowEvery change as it happens, and a Monday email
Trials
4 active
16 in total
What this is
- How it works
- An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
- How it’s given
- “Solution for subcutaneous injection in a prefilled syringe (1 mL) with a concentration of 160 mg/mL, administered as a 64 mg/0.4 mL dose”In the company’s words, NCT07670546 on ClinicalTrials.gov
- Tested for
- Polymyalgia Rheumatica, Still Disease, Lung Diseases, Interstitial, Juvenile Idiopathic Arthritis
- Main trialPhase 3
- “The primary objective of the study is to evaluate the efficacy of olokizumab (OKZ) 64 mg administered subcutaneously every 2 weeks compared with placebo in participants with polymyalgia rheumatica (PMR). The secondary objectives are to evaluate the steroid-sparing effect, inflammatory markers, safety, tolerability, immunogenicity, and pharmacokinetics of OKZ in participants with PMR compared with placebo. The exploratory objectives are to evaluate OKZ efficacy in selected participant subgroups, biomarkers of bone metabolism, pharmacodynamic parameters, glucocorticoid-related effects, and…”In the company’s words, NCT07670546 on ClinicalTrials.gov
- Other names
- Artlegia · CDP6038
Other drugs for Polymyalgia Rheumatica
- SecukinumabNovartis Pharmaceuticals · Phase 3
- SarilumabSanofi · Phase 3
Coming up2
- 9 Apr 2027Phase 2/3 trial completes · ClinicalTrials.gov
- 14 Dec 2027Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials16
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Active, not recruiting | 10 Apr 2026 | Efficacy and Safety of Olokizumab in Patients With Polymyalgia Rheumatica (PROMISE) | |
| Phase 3Not yet recruiting | 14 Dec 2027 | Study of the Efficacy and Safety of Goflikicept and Olokizumab as the Second-line Therapy in Patients With Still's Disease | |
| Phase 2/3Recruiting | 9 Apr 2027 | Efficacy and Safety of Olokizumab in Patients With Progressive Fibrosing Interstitial Lung Diseases | |
| Phase 2Recruiting | Sep 2026 | Pharmacokinetics, Efficacy and Safety of Olokizumab In Patients With Juvenile Idiopathic Arthritis | |
| Phase 3Completed | Aug 2018 | Evaluation of the Effectiveness and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease | |
| Phase 3Completed | 2 Aug 2019 | Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo and Adalimumab, in Subjects With Rheumatoid Arthritis (RA) Who Are Taking Methotrexate But Have Active Disease | |
| Phase 3Completed | 12 Sep 2019 | Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease | |
| Phase 3Completed | 1 Sep 2021 | Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis | |
| Phase 3Unknown | 31 Oct 2022 | Study of Efficacy of Different Treatment Regimens of Olokizumab | |
| Phase 2/3Completed | 10 Jul 2020 | Study of the Efficacy and Safety of a Single Administration of Olokizumab and RPH-104 With Standard Therapy in Patients With Severe Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19) | |
| Phase 2/3Withdrawn | 16 Nov 2020 | Study of the Efficacy and Safety of a Single Administration of Olokizumab vs. Placebo in Addition to Standard Treatment in Patients With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection (COVID-19). | |
| Phase 2Completed | Jun 2012 | Efficacy and Safety of CDP6038 in Patients With Rheumatoid Arthritis With an Unsuccessful Response to Anti-Tumor Necrosis Factor (Anti-TNF) Therapy | |
| Phase 2Terminated | 1 May 2013 | Open-label Study to Assess the Safety and Efficacy of CDP6038 (Olokizumab) in Patients Who Completed RA0056 | |
| Phase 2Terminated | 27 Nov 2013 | The Long-term Safety and Efficacy of CDP6038 (Olokizumab) With Active Rheumatoid Arthritis | |
| Phase 1/2Completed | Sep 2010 | To Evaluate the Blood Levels and Safety of IV and Subcutaneous CDP6038 in Subjects With Rheumatoid Arthritis Using Methotrexate | |
| Phase 1Completed | 8 Jun 2022 | Study in Subjects With Rheumatoid Arthritis to Evaluate the Effect of a Single Dose of Olokizumab on the Pharmacokinetics of Substrates for CYP1A2, CYP2C9, CYP2C19 and CYP3A4 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026